SpringWorks Therapeutics Inc [NASDAQ: SWTX] plunged by -$0.08 during the normal trading session on Thursday and reaching a high of $46.895 during the day while it closed the day at $46.78.
SpringWorks Therapeutics Inc stock has also gained 0.06% of its value over the past 7 days. However, SWTX stock has declined by -7.60% in the 3 months of the year. Over the past six months meanwhile, it has gained 22.14% and gained 29.48% year-on date.
The market cap for SWTX stock reached $3.52 billion, with 74.99 million shares outstanding and 72.94 million shares in the current float. Compared to the average trading volume of 5.24M shares, SWTX reached a trading volume of 8065126 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about SpringWorks Therapeutics Inc [SWTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SWTX shares is $47.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SWTX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for SpringWorks Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 20, 2024. While these analysts kept the previous recommendation, Guggenheim raised their target price to Buy. The new note on the price target was released on February 05, 2024, representing the official price target for SpringWorks Therapeutics Inc stock. Previously, the target price had yet another raise to $45, while BofA Securities analysts kept a Buy rating on SWTX stock. On January 19, 2021, analysts increased their price target for SWTX shares from 87 to 101.
The Average True Range (ATR) for SpringWorks Therapeutics Inc is set at 0.31, with the Price to Sales ratio for SWTX stock in the period of the last 12 months amounting to 16.05. The Price to Book ratio for the last quarter was 8.40, with the Price to Cash per share for the same quarter was set at 3.82.
SWTX stock trade performance evaluation
SpringWorks Therapeutics Inc [SWTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.06. With this latest performance, SWTX shares gained by 1.10% in over the last four-week period, additionally plugging by 22.14% over the last 6 months – not to mention a rise of 21.35% in the past year of trading.
SpringWorks Therapeutics Inc [SWTX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and SpringWorks Therapeutics Inc [SWTX] shares currently have an operating margin of -120.52% and a Gross Margin at 91.48%. SpringWorks Therapeutics Inc’s Net Margin is presently recorded at -115.60%.
Return on Equity for this stock declined to -43.70%, with Return on Assets sitting at -43.70%.
SpringWorks Therapeutics Inc [SWTX]: Institutional Ownership
There are presently around $87.43%, or 88.56%% of SWTX stock, in the hands of institutional investors. The top three institutional holders of SWTX stocks are: FMR LLC with ownership of 11.11 million shares, which is approximately 14.9922%. VANGUARD GROUP INC, holding 6.54 million shares of the stock with an approximate value of $$246.53 million in SWTX stocks shares; and VANGUARD GROUP INC, currently with $$211.68 million in SWTX stock with ownership which is approximately 7.5812%.
